Modern screening tools, coordinated statewide programs, and risk-based guidelines are helping Kentucky physicians detect precancerous polyps—and prevent colorectal cancer before it develops.
Find the polyp. Prevent the cancer.
COLORECTAL CANCER PREVENTION in Kentucky is entering a new phase as screening strategies increasingly focus on preventing cancer, not simply detecting it earlier. Modern screening tools and coordinated statewide programs are helping identify precancerous polyps and stop colorectal cancer before it develops.
Screening efforts across Kentucky have already produced measurable progress. Since coordinated statewide initiatives began around 2000, colorectal cancer incidence and mortality in the Commonwealth have declined by more than 30 percent. This progress translates into approximately 640 cancers prevented and 270 deaths avoided annually, along with roughly $67 million in treatment cost savings according to Tom Tucker, PhD.
These improvements reflect alignment of modern screening guidance, improved access to colonoscopy, statewide policy initiatives, and coordinated statewide implementation.
The urgency of prevention continues to grow. Recent American Cancer Society data show that colorectal cancer is now the leading cause of cancer death among adults younger than 50.1
Kentucky has also strengthened its prevention strategy through policy innovation. Passage of House Bill 421 (KRS 304.17A-257) established insurance coverage for colorectal cancer screening based on U.S. Multi-Society Task Force (USMSTF) elevated-risk recommendations, including earlier screening for individuals with colorectal cancer or advanced adenomas in first-degree relatives.2,3
Clinical Pearls for Colorectal Cancer Prevention
- Advanced adenomas carry nearly the same colorectal cancer risk as colorectal cancer in first-degree relatives (relative risk ~1.9 vs ~2.0), making a family history of polyps clinically important.4 Advanced adenoma is defined as a colorectal polyp meeting at least one of the following criteria: (1) size ≥1 cm as documented by the endoscopist, (2) villous histology, or (3) high-grade dysplasia.2
- Sessile serrated polyps (SSPs) are the predominant precancerous serrated lesion due to their prevalence and malignant potential. Among these lesions, hyperplastic polyps are not considered precancerous, whereas SSPs and traditional serrated adenomas are.5
- Average-risk colorectal cancer screening should begin promptly at age 45.1
- Patients with colorectal cancer or advanced adenoma in a first-degree relative should begin screening at age 40 or ten years before the age of diagnosis of the affected relative.2
- High-quality colonoscopy remains the final pathway to cancer prevention. Low-volume split-dose bowel preparation (LVSD) is now the standard of care to maximize adenoma detection.
Risk Stratification and Lifelong Education
Modern colorectal cancer prevention begins with risk stratification and ongoing patient education. Clinicians should help patients understand their risk based on family history of colorectal cancer or advanced adenomas while remaining attentive to symptoms that may signal sporadic disease.
Screening for average-risk adults should begin promptly at age 45.1 Delayed initiation remains one of the most common reasons screening fails to prevent cancer.
Family history remains one of the strongest predictors of colorectal cancer risk.
The relative risk of colorectal cancer is approximately 2.0 for individuals with a first-degree relative with colorectal cancer and 1.9 for those with a first-degree relative with an advanced adenoma.4
Approximately one in four adults in the U.S. carries an elevated colorectal cancer risk due to family history. For individuals with a first-degree relative with colorectal cancer or an advanced adenoma diagnosed before age 60, screening should begin at age 40 or ten years before the age of diagnosis of the affected relative.2
Even when a first-degree relative is diagnosed at age 60 or older, screening should still begin at age 40.2
Clinicians should review key colorectal cancer symptoms during risk discussions, including rectal bleeding, iron-deficiency anemia, unexplained weight loss, persistent abdominal pain, and persistent changes in bowel habits.
FIT has lower sensitivity for advanced adenomas, including many serrated lesions that do not reliably bleed. Serrated pathway lesions account for up to 30% of colorectal cancers (CRCs).5 Critically, using FIT requires annual compliance, which is rare outside of heavily funded and navigated programs. CT colonography is also an acceptable screening modality for detecting larger polyps and cancers.2
Age 45 should therefore be viewed as the finish line for initiating average-risk screening—not the starting point for clinical awareness.
Clinical informatics is increasingly enabling health systems and community health centers to query electronic health record registries for patients who are overdue for screening or meet elevated-risk criteria. Using these tools at scale is critical for translating colorectal cancer prevention guidelines into real population-level impact.
| Risk Category | Screening Recommendation | Preferred Screening Pathways |
|---|---|---|
| Average risk | Begin screening promptly at age 45 | Colonoscopy, genomic stool testing, or CT colonography6 |
| First-degree relative (FDR) with CRC or advanced adenoma diagnosed before age 60 | Begin screening age 40 or 10 years before diagnosis | Colonoscopy2 |
| First-degree relative (FDR) with CRC or advanced adenoma diagnosed at age ≥60 | Begin screening age 40 | Colonoscopy, genomic stool testing, CT colonography2 |
| Suspected hereditary syndrome | Genetic testing recommended | Syndrome-specific surveillance |
Genetic Testing and Hereditary Cancer Risk
Some patients (15–20%) meet criteria for genetic testing for hereditary colorectal cancer syndromes such as Lynch syndrome according to National Comprehensive Cancer Network (NCCN) guidelines.7
Lynch syndrome is a genetic condition that increases risk of not only CRC but also ovarian, urinary tract, small bowel, stomach, and pancreatic cancers. Families at high risk of Lynch syndrome are identified by the following clinical guidelines known as Amsterdam criteria: (1) ≥ 3 relatives with CRC, (2) cancer involving 2 consecutive generations, (3) one or more relatives diagnosed <50 years old.8
Kentucky addressed financial barriers through the Genetic Testing Access and Awareness Act (2019), which requires insurance coverage for guideline-recommended hereditary cancer genetic testing without patient out-of-pocket costs.9
A Shift in the Biological Target of Screening
Modern colorectal cancer screening now targets not only colorectal cancer itself but also its immediate precursor lesion—the advanced adenoma.
Genomic stool-based screening tests incorporate molecular markers associated with colorectal neoplasia and improve the detection of advanced precancerous lesions compared with traditional fecal immunochemical testing.10 CT colonography also identifies advanced adenomas and CRC with high accuracy. Colonoscopy remains the standard for screening over all other modalities, especially for those determined to be high-risk.
The Emerging Role of Blood-Based Testing
Recent years have seen the development of blood-based colorectal cancer detection tests designed to identify circulating tumor DNA or other cancer-associated signals.
These tests offer convenience but primarily detect existing cancers rather than precancerous lesions, and their sensitivity for advanced adenomas remains limited. Because prevention depends on identifying and removing advanced precancerous lesions, blood-based tests currently occupy a third-tier role in colorectal cancer screening pathways.
Blood-based testing is best viewed as a technological foundation for emerging multi-cancer early detection (MCED) tests that can simultaneously screen for many lethal cancers currently lacking effective screening, such as pancreatic, liver, and ovarian cancers.
Colonoscopy as the Final Common Pathway of Prevention
Regardless of the initial screening modality, colonoscopy remains the final common pathway of colorectal cancer prevention, where advanced adenomas and other precancerous lesions are identified, sampled, and, if possible, removed.
Completion colonoscopy after a positive stool-based, blood-based screening test, and CT colonography is essential. A follow-up colonoscopy should occur promptly—ideally within 2 months—to complete the prevention pathway.11
High-quality bowel preparation is essential for optimal mucosal visualization and adenoma detection.
Low-volume split-dose bowel preparation (LVSD) is now considered the standard of care because it improves cleansing quality and patient tolerability.
Policy Update: Modernizing Colorectal Cancer Screening in Kentucky
Kentucky’s colorectal cancer screening law (HB 421 / KRS 304.17A-257) provides insurance coverage for colorectal cancer screening based on U.S. Multi-Society Task Force (USMSTF) elevated-risk recommendations and requires coverage for low-volume split-dose bowel preparation (LVSD) used for colonoscopy.2,3 These guidelines also help address known risk factors for early-age-onset colorectal cancer by recommending earlier screening for individuals with a family history of colorectal cancer or advanced adenomas.
These coverage provisions apply to Kentucky Medicaid and state-regulated commercial insurance plans, while self-insured employer plans governed by the Employee Retirement Income Security Act of 1974 (ERISA) may not be subject to state insurance mandates.
Kentucky’s Screening Infrastructure
Equally important to Kentucky’s progress is the Kentucky Colon Cancer Screening and Prevention Program (KCCSPP), which functions as a leverage tool for community health centers and safety-net healthcare systems by guaranteeing access to completion colonoscopy for uninsured and underinsured patients after a positive screening test.
Utilization of the program continues to grow, and statewide partners are advocating for increased legislative appropriations to expand access to screening and completion colonoscopy as demand rises across the Commonwealth.
Working with numerous statewide partners—including health systems, academic centers, community health centers, the Kentucky Primary Care Association, public health programs, and professional organizations—the KCCSPP helps deliver colorectal cancer screening at scale and has become a nationally recognized model for statewide cancer prevention.
KCCSPP program information: chfs.ky.gov/agencies/dph/dpqi/cdpb/Pages/coloncancer.aspx
By ensuring access to screening and timely completion colonoscopy across the Commonwealth, these partnerships help translate modern screening strategies into their ultimate goal—finding precancerous polyps and preventing colorectal cancer before it begins.
Looking Forward: A Call to Action
Kentucky has made substantial progress in colorectal cancer prevention over the past two decades. Yet as many as 67% of colorectal cancer deaths remain preventable with current tools.2
The next phase of progress depends on physicians and healthcare systems implementing modern colorectal cancer prevention pathways—including risk-based screening, appropriate test selection, high-quality colonoscopy with optimal bowel preparation, and coordinated follow-up.
The opportunity now is not simply to screen more patients, but to ensure every patient receives the right test at the right time and completes the pathway to cancer prevention.
References
- American Cancer Society. Colorectal Cancer Facts & Figures 2023–2025. Atlanta, GA: American Cancer Society.
- Rex DK, Boland CR, Dominitz JA, et al. Colorectal cancer screening: recommendations for physicians and patients from the U.S. Multi-Society Task Force on Colorectal Cancer. Gastroenterology. 2017;153:307–323.
- Kentucky Revised Statutes §304.17A-257. Coverage for colorectal cancer screening and bowel preparation medications.
- Johns LE, Houlston RS. A systematic review and meta-analysis of familial colorectal cancer risk. Am J Gastroenterol. 2001;96(10):2992–3003.
- Rex DK, Ahnen DJ, Baron JA et al. Serrated lesions of the colorectum: review and recommendations from an expert panel. Am J Gastroenterol. 2012;107:1315–1329.
- Patel, Swati G. et al. Updates on Age to Start and Stop Colorectal Cancer Screening: Recommendations From the U.S. Multi-Society Task Force on Colorectal Cancer. Gastroenterology. 2022;162:285–299.
- Stoffel EM, Kastrinos F. Familial colorectal cancer, beyond Lynch syndrome. Clin Gastroenterol Hepatol. 2014;12(7):1059–68.
- Vasen HF, Mecklin JP, Khan PM, Lynch HT. The International Collaborative Group on Hereditary Non-Polyposis Colorectal Cancer (ICG-HNPCC). Dis Colon Rectum. 1991;34(5):424–5.
- Kentucky Genetic Testing Access and Awareness Act. Kentucky Revised Statutes §304.17A-259.
- Imperiale TF, Ransohoff DF, Itzkowitz SH, et al. Multitarget stool DNA testing for colorectal-cancer screening. New England Journal of Medicine. 2014;370:1287–1297.
- Corley DA, Jensen CD, Quinn VP, et al. Association between time to colonoscopy after a positive fecal test result and risk of colorectal cancer and stage at diagnosis. JAMA. 2017;317:1631–1641.
- Kaminski MF, Regula J, Kraszewska E, et al. Quality indicators for colonoscopy and risk of interval cancer. New England Journal of Medicine. 2010;362:1795–1803.